Ole Andreas Halvorsen
Viking Global Investors
Ole Andreas Halvorsen 4D Molecular TherapeuticsInc stake
total: 670
Viking Global Investors FDMT trades
- Total transactions:
- 4
- New positions:
- 1
- Sold out:
- 1
- Added:
- 1
- Reduced:
- 1
- Held since:
- 2020 Q4
- Held for:
- 15 quarters
- Latest activity:
- 2024 Q3
According to 2026 Q2 report, Ole Andreas Halvorsen doesn't hold any 4D Molecular TherapeuticsInc (FDMT) shares. To date, the estimated cost basis is nearly $37.3 for "buy" trades and estimated average "sell" price is $25.2. Viking Global Investors first purchased FDMT in 2020 Q4, initially acquiring about 3.94M shares. Since the initial investment in 4D Molecular TherapeuticsInc (FDMT), Viking Global Investors has made 3 more transactions.
When did Ole Andreas Halvorsen sell 4D Molecular TherapeuticsInc (FDMT)?
Ole Andreas Halvorsen sold off the entire 4D Molecular TherapeuticsInc (FDMT) position in 2024 Q3.
When did Ole Andreas Halvorsen buy 4D Molecular TherapeuticsInc (FDMT)?
Ole Andreas Halvorsen first invested in 4D Molecular TherapeuticsInc (FDMT) in 2020 Q4 at the reported quarter-end price of $41.45 per share.
What's the cost basis of Viking Global Investors's FDMT stake?
The estimated cost basis for 4D Molecular TherapeuticsInc (FDMT) stake is around $37.30 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $37.30
- Weighted AVG sell price:
- $25.20
Ole Andreas Halvorsen's historical trades in 4D Molecular TherapeuticsInc
4 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2024 Q3
|
0.00%
|
0
|
$20.99
|
|
-100% (-2,934,914)
|
-0.24%
|
|
2024 Q1
|
0.35%
|
2,934,914
|
$31.86
|
$93,506,360
|
-38.70% (-1,853,000)
|
-0.22%
|
|
2023 Q2
|
0.35%
|
4,787,914
|
$18.07
|
$86,517,606
|
+21.59% (+850,000)
|
+0.06%
|
|
2020 Q4
|
0.45%
|
$41.45
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.